DEVELOPMENT OF A MONOCLONAL ANTIBODY AS A THERAPEUTIC TREATMENT IN THE AREA OF INFECTIOUS DISEASES (DAMCLUAB) (Q2024121): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Created claim: summary (P836): * an individual * ediante la TECNOLOGY FOR hybridoma E ha DIMSTRATO EFICCIA blocking THE PROLIFERATION OF FUNGHI OPERATORS. IN ORDER TO INDUSTRIALISE THE PRODUCT, THIS PROJECT RAISES A NUMBER OF OBJECTIVES AND ACTIVITIES: 1) GENERATION OF A CELL LINE FOR INDUSTRIAL SCALE PRODUCTION, (2) PRODUCTION OF A LARGE-SCALE ANTIBODY BATCH, (3) EFFICACY STUDY OF THE MONOCLONAL ANTIBODY IN A MODEL OF INVASIVE ASPERGILLOSIS IN RODENTS. THE CREATION OF A BUSI...) |
||
| Property / summary | |||
* an individual * ediante la TECNOLOGY FOR hybridoma E ha DIMSTRATO EFICCIA blocking THE PROLIFERATION OF FUNGHI OPERATORS. IN ORDER TO INDUSTRIALISE THE PRODUCT, THIS PROJECT RAISES A NUMBER OF OBJECTIVES AND ACTIVITIES: 1) GENERATION OF A CELL LINE FOR INDUSTRIAL SCALE PRODUCTION, (2) PRODUCTION OF A LARGE-SCALE ANTIBODY BATCH, (3) EFFICACY STUDY OF THE MONOCLONAL ANTIBODY IN A MODEL OF INVASIVE ASPERGILLOSIS IN RODENTS. THE CREATION OF A BUSINESS PLAN FOR AN EDI PATENT WILL ASSESS THE MARKET AND DETERMINE THE VALUE OF THE ANTIBODY. THE STUDIES PROPOSED WILL BE CARRIED OUT OVER A PERIOD OF SIX MONTHS AND WILL ALLOW PROGRESS TO BE MADE ON THE ASSOCIATED KNOWLEDGE IN SUPPORT OF INDUSTRIALISATION AND MAY BE THE FIRST STEP TO OBTAIN FURTHER FUNDING, OR TO ESTABLISH A FUTURE STRATEGIC ALLIANCE WITH OTHER COMPANIES TO CONTINUE WITH THE DEVELOPMENT OF ANTIBODIES AS THERAPEUTIC WITH PREPARIO. (English) | |||
| Property / summary: * an individual * ediante la TECNOLOGY FOR hybridoma E ha DIMSTRATO EFICCIA blocking THE PROLIFERATION OF FUNGHI OPERATORS. IN ORDER TO INDUSTRIALISE THE PRODUCT, THIS PROJECT RAISES A NUMBER OF OBJECTIVES AND ACTIVITIES: 1) GENERATION OF A CELL LINE FOR INDUSTRIAL SCALE PRODUCTION, (2) PRODUCTION OF A LARGE-SCALE ANTIBODY BATCH, (3) EFFICACY STUDY OF THE MONOCLONAL ANTIBODY IN A MODEL OF INVASIVE ASPERGILLOSIS IN RODENTS. THE CREATION OF A BUSINESS PLAN FOR AN EDI PATENT WILL ASSESS THE MARKET AND DETERMINE THE VALUE OF THE ANTIBODY. THE STUDIES PROPOSED WILL BE CARRIED OUT OVER A PERIOD OF SIX MONTHS AND WILL ALLOW PROGRESS TO BE MADE ON THE ASSOCIATED KNOWLEDGE IN SUPPORT OF INDUSTRIALISATION AND MAY BE THE FIRST STEP TO OBTAIN FURTHER FUNDING, OR TO ESTABLISH A FUTURE STRATEGIC ALLIANCE WITH OTHER COMPANIES TO CONTINUE WITH THE DEVELOPMENT OF ANTIBODIES AS THERAPEUTIC WITH PREPARIO. (English) / rank | |||
Normal rank | |||
Revision as of 18:10, 23 March 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A MONOCLONAL ANTIBODY AS A THERAPEUTIC TREATMENT IN THE AREA OF INFECTIOUS DISEASES (DAMCLUAB) |
Project in Italy financed by DG Regio |
Statements
40,498.36 Euro
0 references
53,997.82 Euro
0 references
75.0 percent
0 references
7 November 2018
0 references
7 August 2019
0 references
TAKIS SRL
0 references
41°9'9.61"N, 15°5'18.82"E
0 references
UN *individuo*EDIANTE LA TECNOLOGIA DEGLI IBRIDOMI E HA DIMOSTRATO EFFICACIA BLOCCANDO LA PROLIFERAZIONE DEI FUNGHI. ALLO SCOPO DI INDUSTRIALIZZARE IL PRODOTTO, IL PRESENTE PROGETTO SI PONE UNA SERIE DI OBIETTIVI ED ATTIVITÃ : 1) GENERAZIONE DI UNA LINEA CELLULARE PER LA PRODUZIONE IN SCALA INDUSTRIALE, 2) PRODUZIONE DI UN BATCH DI ANTICORPO SU LARGA SCALA, 3) STUDIO DI EFFICACIA DELL'ANTICORPO MONOCLONALE IN UN MODELLO DI ASPERGILLOSI INVASIVA POLMONARE IN RODITORI. LA STESURA DI UN BREVETTO EDI UN BUSINESS PLAN CONSENTIRÃ UNA VALUTAZIONE DEL MERCATO E DI DETERMINARE IL VALORE DELL'ANTICORPO. GLI STUDI PROPOSTI VERRANNO ESEGUITI NELL'ARCO TEMPORALE DI SEI MESI E CONSENTIRANNO UN AVANZAMENTO DELLE CONOSCENZE CONNESSE A SUPPORTO DELL'INDUSTRIALIZZAZIONE E POTRANNO RAPPRESENTARE IL PRIMO PASSO PER L'OTTENIMENTO DI ULTERIORI FINANZIAMENTI, OPPURE PER STABILIRE UNA FUTURA ALLEANZA STRATEGICA CON ALTRE AZIENDE PER PROSEGUIRE NELLO SVILUPPO DEGLI ANTICORPI COME TERAPEUTICI CON LA PREPARAZIO (Italian)
0 references
* an individual * ediante la TECNOLOGY FOR hybridoma E ha DIMSTRATO EFICCIA blocking THE PROLIFERATION OF FUNGHI OPERATORS. IN ORDER TO INDUSTRIALISE THE PRODUCT, THIS PROJECT RAISES A NUMBER OF OBJECTIVES AND ACTIVITIES: 1) GENERATION OF A CELL LINE FOR INDUSTRIAL SCALE PRODUCTION, (2) PRODUCTION OF A LARGE-SCALE ANTIBODY BATCH, (3) EFFICACY STUDY OF THE MONOCLONAL ANTIBODY IN A MODEL OF INVASIVE ASPERGILLOSIS IN RODENTS. THE CREATION OF A BUSINESS PLAN FOR AN EDI PATENT WILL ASSESS THE MARKET AND DETERMINE THE VALUE OF THE ANTIBODY. THE STUDIES PROPOSED WILL BE CARRIED OUT OVER A PERIOD OF SIX MONTHS AND WILL ALLOW PROGRESS TO BE MADE ON THE ASSOCIATED KNOWLEDGE IN SUPPORT OF INDUSTRIALISATION AND MAY BE THE FIRST STEP TO OBTAIN FURTHER FUNDING, OR TO ESTABLISH A FUTURE STRATEGIC ALLIANCE WITH OTHER COMPANIES TO CONTINUE WITH THE DEVELOPMENT OF ANTIBODIES AS THERAPEUTIC WITH PREPARIO. (English)
0 references
Identifiers
B83D18000450007
0 references